查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371889

2030 年 3D 列印藥品市場預測：按劑型、技術、用途、最終用戶和地區進行的全球分析

3D Printed Drugs Market Forecasts to 2030 - Global Analysis By Dosage Form, Technology (Semi Solid Extrusion, Stereolithography, Powder Bed Printing, Thermal Inkjet Printing and Other Technologies), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球3D列印藥品市場規模為9,909萬美元，預計到2030年將達到3.0279億美元，預測期內年複合成長率為17.3%。

3D 列印藥品市場由使用 3D 列印技術以更安全、更有效率的方式專為每位患者製造的藥品結構。這些藥物不需要完全攝入，因為它們的整體多孔結構很容易在口腔中分散。因此，經常吞嚥困難的患者、兒童、老人、中風、阿茲海默症、頭頸癌和其他神經系統問題的患者都可以從這種藥物中受益。

根據世界衛生組織（WHO）統計，2017年全球人均醫療保健支出為1,064.741美元。全球人均醫療保健支出從 2008 年的 864.313 美元增至 2018 年的 1,110.841 美元，其中美國位居榜首，2018 年達到人均 10,623.85 美元。

快速生產與原型製作、複雜的藥物傳輸技術

3D 列印是原型製造和藥物開發的一種快速且經濟實惠的替代。它減少了對耗時且昂貴的傳統製造程序（例如射出成型和錠劑）的需求。此外，透過精確控制藥物釋放的特性，可以3D列印複雜的藥物傳輸系統。透過靶向體內的特定部位並改善藥物輸送，該技術可以提高藥物的功效和安全性。

複雜的製造流程與法規障礙

3D列印藥物的法規環境仍在不斷發展，因此這些產品很難獲得法規的核准。為了確保3D列印藥品的安全、品質和有效性，必須建立強而有力的法律規範和標準。然而，在製藥業實施3D列印技術需要專門的工具和知識。 3D 列印基礎設施的設置和維護成本高昂，需要大量投資。

疾病增加

例如，肺炎導致的兒童死亡人數比其他感染疾病都多，每天約有 2,000 人死亡。其中超過20萬是新生兒。因此，使用3D列印機製造藥物可以讓服藥困難的兒童變得更容易。訂製錠劑的口味、顏色和風格的可能性是這些錠劑的第一個優勢。兒童疾病發病率上升推動了此類藥物的日益普及，預計未來年度3D列印藥物市場將在全球範圍內活躍。

3D列印技術價格昂貴

由於必要的硬體、軟體和材料的初始成本較高，中小型製藥公司可能會發現實施 3D 列印技術具有挑戰性。然而，由於較高的材料成本和較長的製造時間，3D列印藥物的單位成本可能比傳統藥物更高。這可能會減少患者獲得 3D 列印藥物的機會，並減少對這些產品的需求。

新冠肺炎 (COVID-19) 影響：

由於 COVID-19 的爆發，3D 列印的使用增加。為了幫助製造藥品和其他所需產品，先進的製造負責人部署了許多 3D 列印機。此外，由於 COVID-19 大流行導致的藥品短缺，引起了製藥公司對使用 3D 列印技術快速供應藥品的想法的興趣。 COVID-19 大流行預計將對市場擴張產生積極影響。先進的製造業務正在部署許多印表機來為藥品和其他必需產品的生產提供動力。因此，這些技術的使用預計會在 COVID-19 大流行期間擴大。

預計神經病學領域在預測期內將是最大的。

由於帕金森氏症等某些神經系統疾病的患病不斷上升，領域在預測期內佔據了最大佔有率。例如，2015年8月，美國FDA核准了Aprecia Pharmaceutical的SPRITAM（左乙拉西坦）錠劑，這是市面上唯一治療癲癇患者的藥物。這項核准吸引了製藥公司投資該領域，推動了市場成長。此外，2022 年 4 月發表的一篇論文揭示了一群德國和荷蘭科學家如何使用 3D 列印技術製造迷你浮動複方藥丸來治療帕金森氏症。這項研究利用了熔融積層製造 (FDM)。

熱噴墨列印領域預計在預測期內年複合成長率最高

熱噴墨列印領域預計在預測期內年複合成長率最高。熱噴墨列印是一種非接觸式列印技術，利用熱量將微小的墨滴驅動到基板上，形成高解析度的影像和圖案。在 3D 列印治療領域，熱噴墨列印技術能夠精確沉積藥物成分，從而能夠生產具有指定給藥和成分的定製藥物。此外，與其他 3D 列印製程相比，該技術非常經濟，適合各種規模的製藥公司使用。

佔比最大的地區：

由於慢性病的增加、該國擁有良好的醫療基礎設施、對研發的大量投資以及對技術進步的更多利用，亞太地區將在預期期間佔據大部分。此外，由於多種要素，市場正在擴大，包括對廉價藥物和錠劑的需求不斷增加，以及醫療保健行業中 3D 列印的使用不斷增加。 3D 列印藥物越來越受歡迎，因為它們易於攝入並且幾乎可以立即溶解。

複合年複合成長率最高的地區：

由於中國和日本在將 3D 列印藥物技術整合其技術方面取得了相當大的進展，預計亞太地區將在預測期內呈現最高的發展速度。此外，澳洲和印度等新興市場不斷擴大的臨床開發框架、研發和醫療基礎設施為預測期內亞太市場帶來了良好的成長預測。因此，吞嚥困難發生率的上升和醫療基礎設施的擴張預計將推動市場擴張。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 用途分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球3D列印藥品市場：按劑型

  • 奈米顆粒
  • 多重植入物
  • 解決方案
  • 藥片
  • 其他劑型

第6章 全球3D 列印藥品市場：依技術分類

  • 半固體擠出（SSE）
  • 立體光固成型(SLA)
  • 粉紅床印刷
  • 熱噴墨列印
  • 拉鍊劑量
  • 直接寫入
  • 熔融沉積建模
  • 選擇性雷射燒結
  • 其他技術

第7章 全球3D列印藥品市場：依用途

  • 牙科
  • 神經病學
  • 整形外科
  • 兒童用
  • 對於老年人
  • 其他用途

第8章 全球3D 列印藥品市場：依最終用戶分類

  • 研究
  • 醫院和診所
  • 其他最終用戶

第9章 全球3D列印藥品市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Affinity Therapeutics
  • Aprecia Pharmaceuticals LLC
  • Astrazeneca
  • Bioduro
  • Cycle Pharmaceuticals
  • Extend Biosciences
  • Fabrx Ltd
  • Glaxosmithkline PLC
  • Hewlett Packard Caribe
  • Osmotica Pharmaceuticals
Product Code: SMRC23946

According to Stratistics MRC, the Global 3D Printed Drugs Market is accounted for $99.09 million in 2023 and is expected to reach $302.79 million by 2030 growing at a CAGR of 17.3% during the forecast period. The market for 3D-printed drugs consists of pharmaceuticals that are made specifically for each patient in a safer and more efficient manner using 3D printing technology. These medications do not have to be ingested completely because of their unitary porous architecture, which easily disperses in the mouth. Therefore, patients who frequently have swallowing issues, children, the elderly, and those suffering from the effects of stroke, Alzheimer's disease, head and neck cancers, and other neurological problems can all benefit from this type of drug.

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018.

Market Dynamics:

Driver:

Rapid production and prototyping and complex medication delivery techniques

A rapid and affordable alternative for producing prototypes and developing pharmaceuticals is 3D printing. It reduces the need for time- and money-consuming traditional manufacturing procedures like injection molding and tablet compression. Additionally, with precise control over medication release features, complex drug delivery systems can be made through 3D printing. By targeting particular regions of the body and improving drug delivery, this technique can increase the efficacy and safety of medications.

Restraint:

Complex manufacturing processes and regulatory hurdles

Obtaining regulatory approval for these products is difficult, as the regulatory environment for 3D-printed drugs is still developing. A strong regulatory framework and set of criteria must be established in order to guarantee the safety, quality, and effectiveness of 3D-printed drugs. However, specialized tools and knowledge are needed to implement 3D printing technology in the pharmaceutical production industry. The infrastructure for 3D printing can be expensive to set up and maintain, necessitating substantial investments.

Opportunity:

Rising disease prevalence

For instance, pneumonia kills more children than any other infectious disease and causes about 2,000 deaths each day. Newborns make up more than 200,000 of them. Therefore, due to 3D-printed medications, taking medication could become a lot simpler for kids who are averse to doing so. The possibility of customizing the tablet's taste, color, and style is the first advantage of these tablets. The rising adoption of these medications is being influenced by the rising incidence of pediatric disorders, which is expected to fuel the market for 3D-printed drugs globally over the next few years.

Threat:

The cost of 3D printing technology is high

Small and medium-sized pharmaceutical enterprises might find it challenging to embrace 3D printing technology due to the high initial cost of the necessary hardware, software, and materials. However, due to the high cost of materials and the period of time needed for production, 3D-printed pharmaceuticals may have higher prices per unit than conventional drugs. This may lower patient access to 3D-printed medications and lower demand for these products.

COVID-19 Impact:

The use of 3D printing has increased as a result of the COVID-19 outbreak. To assist with the creation of medicines and other necessary products, the operational individuals in the advanced manufacturing industry have introduced a number of 3D printers. Additionally, the COVID-19 pandemic's drug shortages have drawn pharmaceutical companies' attention to the idea of using 3D printing technology to supply medications rapidly. The COVID-19 pandemic is projected to have a favorable effect on market expansion. The operation of businesses in the advanced manufacturing sector has introduced a number of printers to aid in boosting the production of medicines and other essential products. Therefore, it is anticipated that the use of these technologies will grow during the COVID-19 pandemic.

The neurology segment is expected to be the largest during the forecast period

Neurology segment commanded the largest share over the projection period, due to the rise in prevalence of certain neurological conditions, such as Parkinson's disease. For instance, The U.S. FDA approved Aprecia Pharmaceutical's SPRITAM (levetiracetam) tablets in August 2015 as the only approved drug on the market for the treatment of people with epilepsy. This approval has attracted pharmaceutical companies' attention to invest in this segment, driving market growth. Additionally, in an article published in April 2022, a group of scientists from Germany and the Netherlands revealed how they created the Mini-Floating Polypill as a Parkinson's disease treatment using 3D printing technology. This study made use of fused deposition modeling (FDM).

The thermal inkjet printing segment is expected to have the highest CAGR during the forecast period

Thermal Inkjet Printing segment is estimated to witness the highest CAGR over the extrapolated period. Thermal Inkjet Printing is a non-contact printing technology that utilizes heat to drive microscopic droplets of ink onto a substrate, creating high-resolution pictures or patterns. In the context of 3D printed therapeutics, thermal inkjet printing technology allows for the accurate deposition of pharmaceutical ingredients, enabling the fabrication of tailored medications with specified dosages and compositions. Moreover, the technology is reasonably economical compared to other 3D printing processes, making it accessible to pharmaceutical companies of varying sizes.

Region with largest share:

Due to an increased prevalence of chronic diseases, the availability of an outstanding domestic healthcare infrastructure, significant investment in R&D, and the region's expanding utilization of technological advancements, the Asia Pacific region dominated with a majority over the anticipated period. Moreover, the market is expanding due to a number of factors, including the increased need for less expensive medications or tablets and the expanding use of 3D printing in the healthcare industry. Pharmaceuticals produced through 3D printing are gaining popularity as they are simple to consume and almost immediately dissolve.

Region with highest CAGR:

Due to considerable advancements made by China and Japan in the integration of 3D-printed drug techniques into technology, the Asia Pacific is predicted to have the highest rate of development over the projected period. Furthermore, the expansion of clinical development frameworks, R&D, and healthcare infrastructure in developing nations like Australia and India is setting the Asia Pacific market for lucrative growth prospects over the course of the projection period. As a result, rising dysphagia rates and expanding healthcare infrastructure are predicted to drive market expansion.

Key players in the market:

Some of the key players in 3D Printed Drugs market include: Affinity Therapeutics, Aprecia Pharmaceuticals LLC , Astrazeneca, Bioduro, Cycle Pharmaceuticals, Extend Biosciences, Fabrx Ltd, Glaxosmithkline PLC, Hewlett Packard Caribe and Osmotica Pharmaceuticals.

Key Developments:

In October 2022, Cycle Pharmaceuticals Limited (Cycle) announced the launch of JAVYGTOR (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution, as a treatment option for patients with Phenylketonuria (PKU), approved by the US Food and Drug Administration (FDA). The launch of JAVYGTOR continues an established partnership between Cycle and Dr Reddy's Laboratories Ltd, in which the two companies are committed to providing affordable medicines to patients with rare diseases, complemented by the support these patients need.

Dosage Forms Covered:

  • Nanoparticles
  • Multidrug Implant
  • Solutions
  • Tablet
  • Other Dosage Forms

Technologies Covered:

  • Semi Solid Extrusion (SSE)
  • Stereolithography (SLA)
  • Powder Bed Printing
  • Thermal Inkjet Printing
  • Zip Dose
  • Direct Write
  • Fused Deposition Modelling
  • Selective Laser Sintering
  • Other Technologies

Applications Covered:

  • Dental
  • Neurology
  • Orthopedic
  • Children
  • Elderly
  • Other Applications

End Users Covered:

  • Research Laboratories
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global 3D Printed Drugs Market, By Dosage Form

  • 5.1 Introduction
  • 5.2 Nanoparticles
  • 5.3 Multidrug Implant
  • 5.4 Solutions
  • 5.5 Tablet
  • 5.6 Other Dosage Forms

6 Global 3D Printed Drugs Market, By Technology

  • 6.1 Introduction
  • 6.2 Semi Solid Extrusion (SSE)
  • 6.3 Stereolithography (SLA)
  • 6.4 Powder Bed Printing
  • 6.5 Thermal Inkjet Printing
  • 6.6 Zip Dose
  • 6.7 Direct Write
  • 6.8 Fused Deposition Modelling
  • 6.9 Selective Laser Sintering
  • 6.10 Other Technologies

7 Global 3D Printed Drugs Market, By Application

  • 7.1 Introduction
  • 7.2 Dental
  • 7.3 Neurology
  • 7.4 Orthopedic
  • 7.5 Children
  • 7.6 Elderly
  • 7.7 Other Applications

8 Global 3D Printed Drugs Market, By End User

  • 8.1 Introduction
  • 8.2 Research Laboratories
  • 8.3 Hospitals & Clinics
  • 8.4 Other End Users

9 Global 3D Printed Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Affinity Therapeutics
  • 11.2 Aprecia Pharmaceuticals LLC
  • 11.3 Astrazeneca
  • 11.4 Bioduro
  • 11.5 Cycle Pharmaceuticals
  • 11.6 Extend Biosciences
  • 11.7 Fabrx Ltd
  • 11.8 Glaxosmithkline PLC
  • 11.9 Hewlett Packard Caribe
  • 11.10 Osmotica Pharmaceuticals

List of Tables

  • Table 1 Global 3D Printed Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global 3D Printed Drugs Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 3 Global 3D Printed Drugs Market Outlook, By Nanoparticles (2021-2030) ($MN)
  • Table 4 Global 3D Printed Drugs Market Outlook, By Multidrug Implant (2021-2030) ($MN)
  • Table 5 Global 3D Printed Drugs Market Outlook, By Solutions (2021-2030) ($MN)
  • Table 6 Global 3D Printed Drugs Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 7 Global 3D Printed Drugs Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 8 Global 3D Printed Drugs Market Outlook, By Technology (2021-2030) ($MN)
  • Table 9 Global 3D Printed Drugs Market Outlook, By Semi Solid Extrusion (SSE) (2021-2030) ($MN)
  • Table 10 Global 3D Printed Drugs Market Outlook, By Stereolithography (SLA) (2021-2030) ($MN)
  • Table 11 Global 3D Printed Drugs Market Outlook, By Powder Bed Printing (2021-2030) ($MN)
  • Table 12 Global 3D Printed Drugs Market Outlook, By Thermal Inkjet Printing (2021-2030) ($MN)
  • Table 13 Global 3D Printed Drugs Market Outlook, By Zip Dose (2021-2030) ($MN)
  • Table 14 Global 3D Printed Drugs Market Outlook, By Direct Write (2021-2030) ($MN)
  • Table 15 Global 3D Printed Drugs Market Outlook, By Fused Deposition Modelling (2021-2030) ($MN)
  • Table 16 Global 3D Printed Drugs Market Outlook, By Selective Laser Sintering (2021-2030) ($MN)
  • Table 17 Global 3D Printed Drugs Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 18 Global 3D Printed Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 Global 3D Printed Drugs Market Outlook, By Dental (2021-2030) ($MN)
  • Table 20 Global 3D Printed Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 21 Global 3D Printed Drugs Market Outlook, By Orthopedic (2021-2030) ($MN)
  • Table 22 Global 3D Printed Drugs Market Outlook, By Children (2021-2030) ($MN)
  • Table 23 Global 3D Printed Drugs Market Outlook, By Elderly (2021-2030) ($MN)
  • Table 24 Global 3D Printed Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global 3D Printed Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global 3D Printed Drugs Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 27 Global 3D Printed Drugs Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 28 Global 3D Printed Drugs Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.